Related Experiment Video

Updated: May 6, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

16.4K

Angiotensin I converting enzyme gene polymorphism and coronary heart disease

F Cambien1, A Evans

  • 1INSERM, Paris, France.

European Heart Journal
|November 1, 1995
PubMed

Insights

Genetic variations in the renin-angiotensin system, specifically angiotensin converting enzyme (ACE) gene polymorphism, are linked to increased risks of heart attack and death. This genetic factor may influence heart conditions, but further research is needed.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Pharmacogenomics

Background:

  • Genetic variations in the renin-angiotensin and kallikrein-kinin systems play a role in coronary heart disease (CHD) pathophysiology.
  • Angiotensin II and bradykinin are potent vasoactive substances implicated in cardiovascular events.
  • Angiotensin converting enzyme (ACE) gene polymorphism is associated with increased risk of myocardial infarction and death.

Purpose of the Study:

  • To investigate the role of ACE gene polymorphism in cardiovascular disease.
  • To explore the influence of ACE polymorphism on left ventricular mass and hypertrophy.
  • To assess the clinical implications of ACE-angiotensin II type-1 receptor interactions in CHD management.

Main Methods:

  • Analysis of genetic variations, specifically ACE gene polymorphism.
  • Correlation of genetic factors with cardiovascular events like myocardial infarction and death.
  • Examination of the impact of ACE polymorphism on cardiac structure and function.

Main Results:

  • ACE gene polymorphism is linked to elevated risk of myocardial infarction and death, even in low-risk individuals.
  • Genetic factors do not appear to be primary risks for atherosclerosis or hypertension.
  • ACE polymorphism influences local angiotensin II production, potentially affecting left ventricular mass.

Conclusions:

  • ACE polymorphism may impact left ventricular mass, particularly in conjunction with hypertension or cardiomyopathy.
  • Further studies are required to fully understand ACE polymorphism implications in left ventricular hypertrophy.
  • Targeting ACE and angiotensin II type-1 receptors with drugs like ACE inhibitors may offer therapeutic benefits for CHD.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K